Efficacy and Safety of HRS9531 in Overweight or Obese Participants: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Latest Information Update: 31 May 2024
At a glance
- Drugs HRS 9531 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 29 May 2024 Status changed from not yet recruiting to recruiting.
- 08 May 2024 New trial record